{"id":"2e95b1d2-4526-5b05-bcd1-f0985caac578","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-cd38-cyclase","predicate":"decreases_in_recorded_comparison","statement":"Apigenin inhibited human CD38 ADP-ribosyl cyclase activity with IC50 12.8 ± 1.6 micromolar.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"bd879e55-8ea1-5f86-9a6d-e8337df9e1a0","mechanism_event_label":"Apigenin inhibited human CD38 ADP-ribosyl cyclase activity with IC50 12.8 ± 1.6 micromolar.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"fddfde71-6536-5ac2-82cd-5942ad68b116","slug":"cd38","display_name":"Human CD38","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"bd879e55-8ea1-5f86-9a6d-e8337df9e1a0","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-cd38-cyclase-event","event_type":"biochemical_relationship","label":"Apigenin inhibited human CD38 ADP-ribosyl cyclase activity with IC50 12.8 ± 1.6 micromolar.","description":"### api-human-cd38-cyclase\n\nApigenin inhibited human CD38 ADP-ribosyl cyclase activity with IC50 12.8 ± 1.6 micromolar.\nSeparate assay from NAD hydrolysis.\nModel and exposure: Recombinant soluble enzyme; cyclase assay.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.\nReference: Erratum: Apigenin inhibits the NADase CD38 | 2014 | https://doi.org/10.2337/db14-er04 | Access: Publisher erratum PDF read: Figures 3, 4 and 5 concentration axes should not be labelled Log[concentration]; the scale itself is logarithmic.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin concentration series","sequence_order":0,"notes":""},{"entity":{"id":"fddfde71-6536-5ac2-82cd-5942ad68b116","slug":"cd38","display_name":"Human CD38","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"55ff303e-ae6b-5adf-b34f-a11a53812e9a","slug":"cyclic-adp-ribose","display_name":"Cyclic ADP-ribose","entity_type_key":"small_molecule"},"role":"native cyclase product","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.; Publisher erratum PDF read: Figures 3, 4 and 5 concentration axes should not be labelled Log[concentration]; the scale itself is logarithmic.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin concentration series\", \"comparator\": \"Enzyme without inhibitor\", \"endpoint\": \"Apigenin inhibited human CD38 ADP-ribosyl cyclase activity with IC50 12.8 ± 1.6 micromolar.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Recombinant soluble enzyme; cyclase assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin inhibited human CD38 ADP-ribosyl cyclase activity with IC50 12.8 ± 1.6 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Erratum: Apigenin inhibits the NADase CD38 | https://doi.org/10.2337/db14-er04","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-human-cd38-cyclase; Separate assay from NAD hydrolysis.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6104d184-d23f-5654-9f63-231d53cc2ead","evidence_kind":"source_excerpt","locator":"Lines 159-166","start_line":159,"end_line":166,"excerpt":"### api-human-cd38-cyclase\n\nApigenin inhibited human CD38 ADP-ribosyl cyclase activity with IC50 12.8 ± 1.6 micromolar.\nSeparate assay from NAD hydrolysis.\nModel and exposure: Recombinant soluble enzyme; cyclase assay.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.\nReference: Erratum: Apigenin inhibits the NADase CD38 | 2014 | https://doi.org/10.2337/db14-er04 | Access: Publisher erratum PDF read: Figures 3, 4 and 5 concentration axes should not be labelled Log[concentration]; the scale itself is logarithmic.","model_system":"Recombinant soluble enzyme; cyclase assay.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}